The efficacy of tobramycin in the treatment of ulcerative colitis

Burke, Dave; Axon, A. T. R.; Clayden, S.A.; Dixon, M. F.; Johnston, D.; Lacey, R. W.

doi:10.1111/j.1365-2036.1990.tb00456.x

Cited by 161 publications

(56 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, antibiotics can transiently diminish IBD activity even in absence of CDI. [19][20][21] Similarly, absence of a clear antibiotic trigger temporally associated with the initial diagnosis of CDI is not a reliable factor because IBD alone can be associated with marked dysbiosis, sufficient to allow CDI.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Recurrent Clostridium Difficile Infection using Fecal Microbiota Transplantation in Patients with Inflammatory Bowel Disease

Newman¹,

Rank²,

Vaughn³

et al. 2017

Gastroenterology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Treatment of Recurrent Clostridium Difficile Infection using Fecal Microbiota Transplantation in Patients with Inflammatory Bowel Disease

Newman¹,

Rank²,

Vaughn³

et al. 2017

Gastroenterology

View full text Add to dashboard Cite

“…Several RCTs are available regarding the use of antibiotics in the treatment of active UC [60,61,62,63,64,65,66,67,68,69,70]; the 2011 meta-analysis [14] included 9 that matched the quality criteria and give remission as an outcome [60,62,64,65,66,67,68,69,70]. These trials involved 662 patients with mostly moderately active UC, and they tested metronidazole, ciprofloxacin, tobramycin, vancomycin, amoxicillin, tetracycline and rifaximin, alone or in combination.…”

Section: Review Of the Evidencementioning

confidence: 99%

The Role of Anti(myco)bacterial Interventions in the Management of IBD: Is There Evidence at All?

Chambrun¹,

Torres

Darfeuille‐Michaud

et al. 2012

Dig Dis

View full text Add to dashboard Cite

Background/Aims: The etiology of IBD is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn’s disease (CD) and ulcerative colitis (UC). The aim of this review was to compel the evidence for the use of antibiotics in the treatment of IBD. Methods: We performed a systematic review of the literature regarding the use of antibiotics for inducing or maintaining remission in IBD. Results: Current data are conflicting, but a recent systematic review of randomized controlled trials has shown a statistically significant effect of antibiotics being superior to placebo for active, perianal and quiescent CD and for active UC. These data have been poorly translated in clinical practice and the place of antibiotics is restricted to certain specific situations in the international guidelines. This is first linked to the difficulties in interpreting clinical trials because of their heterogeneity in study design, endpoints, type of antibiotic and concomitant therapies. The exception to this is the use of either ciprofloxacin or metronidazole for treating CD perianal fistulas. Conclusion: The pathology of CD, the likely primary and known secondary pathogens in this disease and the successful responses in animal models all plead for new trials of antibiotics in IBD. This is a call to select patients more carefully, and to continue antibiotics for longer than is customary. Beside antibiotics, new therapeutic approaches that can balance gut dysbiosis should be tested.

show abstract

“…Evidence implicating the resident enteric microflora in the pathogenesis of spontaneous IBD in people is provided by the increased immune responses to enteric commensal bacteria observed in both Crohn's disease (CD) and ulcerative colitis (UC) (1,24,45,52,54), the clinical responses of CD and UC to antimicrobials (9,10,48,58,70) and the response of CD to fecal stream diversion (68). The discovery of genetic defects in the microflora-sensing ability of patients with CD and UC, such as NOD2/CARD15 and TLR-4, respectively, provides mechanisms to explain individual susceptibility to the resident microflora (33,46).…”

mentioning

confidence: 99%

Adherent and InvasiveEscherichia coliIs Associated with Granulomatous Colitis in Boxer Dogs

Simpson¹,

Dogan²,

Rishniw³

et al. 2006

Infect Immun

236

320

View full text Add to dashboard Cite

The mucosa-associated microflora is increasingly considered to play a pivotal role in the pathogenesis of inflammatory bowel disease. This study explored the possibility that an abnormal mucosal flora is involved in the etiopathogenesis of granulomatous colitis of Boxer dogs (GCB). Colonic biopsy samples from affected dogs (n ‫؍‬ 13) and controls (n ‫؍‬ 38) were examined by fluorescent in situ hybridization (FISH) with a eubacterial 16S rRNA probe. Culture, 16S ribosomal DNA sequencing, and histochemistry were used to guide subsequent FISH. GCB-associated Escherichia coli isolates were evaluated for their ability to invade and persist in cultured epithelial cells and macrophages as well as for serotype, phylogenetic group, genome size, overall genotype, and presence of virulence genes. Intramucosal gram-negative coccobacilli were present in 100% of GCB samples but not controls. Invasive bacteria hybridized with FISH probes to E. coli. Three of four GCB-associated E. coli isolates adhered to, invaded, and replicated within cultured epithelial cells. Invasion triggered a "splash"-type response, was decreased by cytochalasin D, genistein, colchicine, and wortmannin, and paralleled the behavior of the Crohn's disease-associated strain E. coli LF 82. GCB E. coli and LF 82 were diverse in serotype and overall genotype but similar in phylogeny (B2 and D), in virulence gene profiles (fyuA, irp1, irp2, chuA, fepC, ibeA, kpsMII, iss), in having a larger genome size than commensal E. coli, and in the presence of novel multilocus sequence types. We conclude that GCB is associated with selective intramucosal colonization by E. coli. E. coli strains associated with GCB and Crohn's disease have an adherent and invasive phenotype and novel multilocus sequence types and resemble E. coli associated with extraintestinal disease in phylogeny and virulence gene profile.

show abstract

The efficacy of tobramycin in the treatment of ulcerative colitis

Cited by 161 publications

References 21 publications

Treatment of Recurrent Clostridium Difficile Infection using Fecal Microbiota Transplantation in Patients with Inflammatory Bowel Disease

Treatment of Recurrent Clostridium Difficile Infection using Fecal Microbiota Transplantation in Patients with Inflammatory Bowel Disease

The Role of Anti(myco)bacterial Interventions in the Management of IBD: Is There Evidence at All?

Adherent and InvasiveEscherichia coliIs Associated with Granulomatous Colitis in Boxer Dogs

Contact Info

Product

Resources

About